All In Biotech

Drug Trial Radar · NCT02032004

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure

Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1

Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 565 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

565

Actual

Start

Mar 3, 2014

Primary completion

Jan 30, 2020

Study completion Jan 30, 2020

Sponsor

Lead sponsor
Mesoblast, Inc.Industry
Sponsor type
Industry
First posted
Jan 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine whether transendocardial delivery of allogeneic human bone marrow-derived mesenchymal precursor cells (MPCs \[rexlemestrocel-L\]) is effective in the treatment of chronic heart failure (HF) due to left ventricular (LV) systolic dysfunction.

Conditions

  • Chronic Heart Failure

Interventions

  • Rexlemestrocel-LBiological

    Rexlemestrocel-L consists of human bone marrow-derived allogeneic mesenchymal precursor cells (MPCs) isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo, and cryopreserved.

  • Sham ComparatorOther

    The sham procedure was staged to script and did not include actual cardiac mapping or delivery of rexlemestrocel-L.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Recurrent Non-fatal Decompensated Heart Failure Major Adverse Cardiac Events (HF-MACE) That Occur Prior to the First Terminal Cardiac Event (TCE)Time frame: Up to 71 months

Locations

59 sites in 2 countries. Site status is shown where the registry gives one.

  • Mesoblast Investigational Site 10757 - Cardiology, P.C.

    Birmingham, Alabama

  • Mesoblast Investigational Site 13262 - University of Alabama at Birmingham Hospital

    Birmingham, Alabama

  • Mesoblast Investigational Site 10779 - Mercy Gilbert Medical Center

    Gilbert, Arizona

  • Mesoblast Investigational Site 10786 - Cardiovascular Associates of Mesa

    Mesa, Arizona

  • Mesoblast Investigational Site 10756 - Mayo Clinic

    Phoenix, Arizona

  • Mesoblast Investigational Site 13023 - University of Arizona Medical Center

    Tucson, Arizona

  • Mesoblast Investigational Site 10754 - University of California, San Diego

    La Jolla, California

  • Mesoblast Investigational Site 10759 - Scripps Clinic

    La Jolla, California

  • Mesoblast Investigational Site 13265 - University of California, Los Angeles

    Los Angeles, California

  • Mesoblast Investigational Site 10775 - Cedars-Sinai Medical Care Foundation

    Los Angeles, California

  • Mesoblast Investigational Site 10778 - Orange County Cardiology

    Orange, California

  • Mesoblast Investigational Site 13031 - St. John's Regional Medical Center

    Oxnard, California

  • Mesoblast Investigational Site 13275 - Stanford University Hospital

    Stanford, California

  • Mesoblast Investigational Site 13267 - Bethesda Heart Hospital

    Boynton Beach, Florida

  • Mesoblast Investigational Site 10780 - Morton Plant Hospital

    Clearwater, Florida

  • Mesoblast Investigational Site 10760 - Shands Hospital, University of Florida

    Gainesville, Florida

  • Mesoblast Investigational Site 13273 - University of Florida Health

    Jacksonville, Florida

  • Mesoblast Investigational Site 10768 - University of Miami

    Miami, Florida

  • Mesoblast Investigational Site 13280

    Orlando, Florida

  • Mesoblast Investigational Site 13264 - Florida Hospital Pepin Heart Institute

    Tampa, Florida

  • Mesoblast Investigational Site 13027 - Emory University School of Medicine

    Atlanta, Georgia

  • Mesoblast Investigational Site 10765 - Georgia Regents University

    Augusta, Georgia

  • Mesoblast Investigational Site 10772 - University Cardiologist, Rush University Medical Center

    Chicago, Illinois

  • Mesoblast Investigational Site 13030 - University of Iowa

    Iowa City, Iowa

  • Mesoblast Investigational Site 10783 - Gill Heart Institute, University of Kentucky

    Lexington, Kentucky

  • Mesoblast Investigational Site 13022 - University of Louisville

    Louisville, Kentucky

  • Mesoblast Investigational Site 13266

    New Orleans, Louisiana

  • Mesoblast Investigational Site 10782

    Boston, Massachusetts

  • Mesoblast Investigational Site 10766 - Michigan Cardiovascular Institute

    Saginaw, Michigan

  • Mesoblast Investigational Site 10762 - Minneapolis Heart Institute

    Minneapolis, Minnesota

  • Mesoblast Investigational Site 10761 - Mayo Clinic

    Rochester, Minnesota

  • Mesoblast Investigational Site 13281

    Las Vegas, Nevada

  • Mesoblast Investigational Site 13263 - RWJ Barnabas Heart Center

    Newark, New Jersey

  • Mesoblast Investigational Site 10776 - Columbia University Medical Center

    New York, New York

  • Mesoblast Investigational Site 13026 - Sanger Heart and Vascular Institute, Carolinas Healthcare System

    Charlotte, North Carolina

  • Mesoblast Investigational Site 10781 - Duke University

    Durham, North Carolina

  • Mesoblast Investigational Site 10758 - The Christ Hospital

    Cincinnati, Ohio

  • Mesoblast Investigational Site 10770 - University of Cincinnati

    Cincinnati, Ohio

  • Mesoblast Investigational Site 10773

    Cleveland, Ohio

  • Mesoblast Investigational Site 13278 - OhioHealth Research Institute

    Columbus, Ohio

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.